clinical trial · NCT06618287
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Bristol-Myers Squibb·phase2·recruiting·n = 416
Lung CancerBreast CancerBMS-986507OsimertinibPembrolizumabNivolumabPumitamig
brief summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
started
Feb 4, 2025
primary completion
Feb 26, 2031
completion
Feb 26, 2031
last updated
May 7, 2026
official title
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol